Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis

Amyloid. 2019;26(sup1):71-72. doi: 10.1080/13506129.2019.1583192.

Authors

Natalia Ruiz-Negrón¹, Jose Nativi-Nicolau², Mathew S Maurer³, Andrew E Moran⁴, Tibor Kovacsovics², Brandon K Bellows¹

Affiliations

¹ a Department of Pharmacotherapy, University of Utah College of Pharmacy , Salt Lake City , UT , USA.
² b Department of Internal Medicine, University of Utah School of Medicine , Salt Lake City , UT , USA.
³ c Division of Cardiology, College of Physicians & Surgeons, Columbia University , New York City , NY , USA.
⁴ d Division of General Medicine, College of Physicians & Surgeons, Columbia University , New York City , NY , USA.

PMID: 31343305
DOI: 10.1080/13506129.2019.1583192

No abstract available

MeSH terms

Aged
Aged, 80 and over
Amyloid Neuropathies, Familial / diagnosis*
Amyloid Neuropathies, Familial / diagnostic imaging
Amyloid Neuropathies, Familial / genetics
Amyloid Neuropathies, Familial / physiopathology
Biopsy / methods*
Female
Heart / diagnostic imaging*
Heart / physiopathology
Humans
Male
Middle Aged
Prealbumin / genetics
Radionuclide Imaging / methods*
Technetium / therapeutic use

Substances

Prealbumin
Technetium

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related